Niagen Bioscience (NAGE) Competitors

Niagen Bioscience has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Niagen Bioscience has a net margin of 13.43% compared to Damora Therapeutics, Inc. Common Stock's net margin of 0.00%. Niagen Bioscience's return on equity of 21.10% beat Damora Therapeutics, Inc. Common Stock's return on equity.

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 10.5% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Comparatively, 9.4% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Damora Therapeutics, Inc. Common Stock had 2 more articles in the media than Niagen Bioscience. MarketBeat recorded 3 mentions for Damora Therapeutics, Inc. Common Stock and 1 mentions for Niagen Bioscience. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.02 beat Niagen Bioscience's score of 0.00 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Damora Therapeutics, Inc. Common Stock currently has a consensus target price of $43.40, suggesting a potential upside of 74.51%. Niagen Bioscience has a consensus target price of $15.00, suggesting a potential upside of 211.20%. Given Niagen Bioscience's higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than Damora Therapeutics, Inc. Common Stock.

Damora Therapeutics, Inc. Common Stock has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.

Niagen Bioscience has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Niagen Bioscience has a net margin of 13.43% compared to Precigen's net margin of -2,588.21%. Precigen's return on equity of 2,317.96% beat Niagen Bioscience's return on equity.

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 9.4% of Niagen Bioscience shares are owned by company insiders. Comparatively, 47.1% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Precigen had 4 more articles in the media than Niagen Bioscience. MarketBeat recorded 5 mentions for Precigen and 1 mentions for Niagen Bioscience. Precigen's average media sentiment score of 0.64 beat Niagen Bioscience's score of 0.00 indicating that Precigen is being referred to more favorably in the news media.

Niagen Bioscience presently has a consensus target price of $15.00, suggesting a potential upside of 211.20%. Precigen has a consensus target price of $9.50, suggesting a potential upside of 119.40%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, equities research analysts plainly believe Niagen Bioscience is more favorable than Precigen.

Niagen Bioscience has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.

Niagen Bioscience has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Niagen Bioscience has a net margin of 13.43% compared to Ardelyx's net margin of -13.58%. Niagen Bioscience's return on equity of 21.10% beat Ardelyx's return on equity.

In the previous week, Ardelyx had 22 more articles in the media than Niagen Bioscience. MarketBeat recorded 23 mentions for Ardelyx and 1 mentions for Niagen Bioscience. Ardelyx's average media sentiment score of 0.28 beat Niagen Bioscience's score of 0.00 indicating that Ardelyx is being referred to more favorably in the news media.

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 9.4% of Niagen Bioscience shares are owned by company insiders. Comparatively, 4.8% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Niagen Bioscience has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.

Niagen Bioscience presently has a consensus target price of $15.00, suggesting a potential upside of 211.20%. Ardelyx has a consensus target price of $15.70, suggesting a potential upside of 120.20%. Given Niagen Bioscience's higher probable upside, equities research analysts plainly believe Niagen Bioscience is more favorable than Ardelyx.

Niagen Bioscience has higher earnings, but lower revenue than Harrow. Harrow is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Niagen Bioscience has a net margin of 13.43% compared to Harrow's net margin of -1.89%. Harrow's return on equity of 36.51% beat Niagen Bioscience's return on equity.

In the previous week, Harrow had 3 more articles in the media than Niagen Bioscience. MarketBeat recorded 4 mentions for Harrow and 1 mentions for Niagen Bioscience. Harrow's average media sentiment score of 0.60 beat Niagen Bioscience's score of 0.00 indicating that Harrow is being referred to more favorably in the news media.

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 9.4% of Niagen Bioscience shares are owned by insiders. Comparatively, 12.8% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Niagen Bioscience has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Comparatively, Harrow has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.

Niagen Bioscience presently has a consensus target price of $15.00, suggesting a potential upside of 211.20%. Harrow has a consensus target price of $69.86, suggesting a potential upside of 72.49%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, research analysts plainly believe Niagen Bioscience is more favorable than Harrow.